News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
295,218 Results
Type
Article (15457)
Company Profile (299)
Press Release (279455)
Multimedia
Podcasts (96)
Webinars (12)
Section
Business (81762)
Career Advice (165)
Deals (13910)
Drug Delivery (44)
Drug Development (51173)
Employer Resources (31)
FDA (6047)
Job Trends (5240)
News (148386)
Policy (10371)
Tag
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (946)
Accelerated approval (27)
Adcomms (14)
Allergies (100)
Alliances (22666)
ALS (162)
Alzheimer's disease (1132)
Antibody-drug conjugate (ADC) (375)
Approvals (6332)
Artificial intelligence (354)
Autoimmune disease (242)
Automation (10)
Bankruptcy (105)
Best Places to Work (4593)
BIOSECURE Act (6)
Biosimilars (127)
Biotechnology (228)
Bladder cancer (123)
Brain cancer (57)
Breast cancer (425)
Cancer (3920)
Cardiovascular disease (289)
Career advice (154)
Career pathing (10)
CAR-T (268)
CDC (8)
Celiac Disease (1)
Cell therapy (716)
Cervical cancer (22)
Clinical research (45088)
Collaboration (1447)
Company closure (3)
Compensation (750)
Complete response letters (55)
COVID-19 (1131)
CRISPR (106)
C-suite (752)
Cystic fibrosis (119)
Data (5632)
Denatured (20)
Depression (114)
Dermatology (55)
Diabetes (302)
Diagnostics (1533)
Digital health (16)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (258)
Drug pricing (52)
Drug shortages (4)
Duchenne muscular dystrophy (271)
Earnings (33171)
Editorial (33)
Employer branding (4)
Employer resources (29)
Events (53782)
Executive appointments (692)
FDA (8215)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (17)
Frontotemporal dementia (31)
Funding (1178)
Gene editing (225)
Generative AI (30)
Gene therapy (602)
GLP-1 (557)
Government (1189)
Grass and pollen (3)
Guidances (174)
Healthcare (6804)
HIV (28)
Huntington's disease (50)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (85)
Immunology and inflammation (235)
Immuno-oncology (75)
Indications (127)
Infectious disease (1280)
Inflammatory bowel disease (182)
Inflation Reduction Act (10)
Influenza (55)
Intellectual property (201)
Interviews (19)
IPO (7438)
IRA (13)
Job creations (891)
Job search strategy (132)
JPM (41)
Kidney cancer (9)
Labor market (29)
Layoffs (252)
Leadership (13)
Legal (1516)
Liver cancer (45)
Longevity (24)
Lung cancer (513)
Lymphoma (290)
Machine learning (33)
Management (7)
Manufacturing (516)
MASH (154)
Medical device (2861)
Medtech (2881)
Mergers & acquisitions (7203)
Metabolic disorders (872)
mRNA (158)
Multiple sclerosis (123)
NASH (14)
Neurodegenerative disease (314)
Neuropsychiatric disorders (81)
Neuroscience (2274)
Neurotech (1)
NextGen: Class of 2026 (2063)
Non-profit (877)
Now hiring (39)
Obesity (392)
Opinion (139)
Ovarian cancer (180)
Pain (134)
Pancreatic cancer (220)
Parkinson's disease (292)
Partnered (12)
Patents (384)
Patient recruitment (491)
Peanut (47)
People (27530)
Pharmaceutical (42)
Pharmacy benefit managers (6)
Phase 1 (15946)
Phase 2 (20982)
Phase 3 (13223)
Pipeline (5773)
Policy (103)
Postmarket research (874)
Preclinical (6772)
Press Release (30)
Prostate cancer (194)
Psychedelics (58)
Radiopharmaceuticals (274)
Rare diseases (855)
Real estate (1551)
Recruiting (12)
Regulatory (10690)
Reports (21)
Research institute (993)
Resumes & cover letters (20)
Rett syndrome (35)
RNA editing (27)
RSV (24)
Schizophrenia (145)
Series A (230)
Series B (159)
Service/supplier (2)
Sickle cell disease (90)
Special edition (20)
Spinal muscular atrophy (125)
Sponsored (17)
Startups (2059)
State (1)
Stomach cancer (5)
Supply chain (39)
Tariffs (19)
The Weekly (74)
Vaccines (392)
Venture capital (85)
Weight loss (209)
Women's health (45)
Worklife (2)
Date
Today (69)
Last 7 days (293)
Last 30 days (2007)
Last 365 days (17977)
2026 (7725)
2025 (18235)
2024 (20723)
2023 (22678)
2022 (27895)
2021 (28768)
2020 (24036)
2019 (16580)
2018 (11989)
2017 (14103)
2016 (12130)
2015 (14800)
2014 (10725)
2013 (7753)
2012 (7878)
2011 (7943)
2010 (7696)
Location
Africa (157)
Alabama (72)
Alaska (2)
Arizona (82)
Arkansas (6)
Asia (18922)
Australia (3261)
California (8440)
Canada (2181)
China (976)
Colorado (303)
Connecticut (312)
Delaware (293)
Europe (43099)
Florida (1085)
Georgia (249)
Hawaii (2)
Idaho (18)
Illinois (498)
India (45)
Indiana (197)
Iowa (8)
Japan (306)
Kansas (83)
Kentucky (12)
Louisiana (14)
Maine (12)
Maryland (875)
Massachusetts (6697)
Michigan (131)
Minnesota (301)
Mississippi (3)
Missouri (35)
Montana (17)
Nebraska (6)
Nevada (47)
New Hampshire (22)
New Jersey (1931)
New Mexico (13)
New York (2095)
North Carolina (986)
North Dakota (7)
Northern California (4266)
Ohio (212)
Oklahoma (11)
Oregon (23)
Pennsylvania (1628)
Puerto Rico (11)
Rhode Island (27)
South America (223)
South Carolina (12)
Southern California (3375)
Tennessee (49)
Texas (1146)
United States (27986)
Utah (123)
Virginia (171)
Washington D.C. (37)
Washington State (687)
West Virginia (1)
Wisconsin (56)
295,218 Results for "acousia therapeutics gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors.
January 9, 2024
·
2 min read
Press Releases
TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH
April 29, 2026
·
5 min read
Press Releases
Veld Pharmaceuticals GmbH Announces Collaboration with Chiesi Farmaceutici S.p.A to Expand Access to Rare Disease Therapies Across Africa
April 14, 2026
·
1 min read
Drug Development
Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Acousia Therapeutics received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ACOU085 in patients with cisplatin-induced hearing loss.
October 9, 2023
·
2 min read
Drug Development
Hearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose.
December 12, 2022
·
1 min read
Press Releases
IBA integrates Artificial Intelligence Quality Assurance into dosimetry solutions through the acquisition of PhantomX GmbH
November 3, 2025
·
2 min read
Press Releases
Croma-Pharma GmbH Enters Strategic Distribution Partnership with Renellence in Canada
October 10, 2025
·
2 min read
Mergers & acquisitions
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities
Gilead Sciences has inked three deals this year so far totaling $14.77 billion, a marked escalation of the company’s usual M&A pace. Executives detailed the rationale for buying Arcellx, Ouro Medicine and Tubulis GmbH and whether they are interested in further deals.
April 8, 2026
·
5 min read
·
Annalee Armstrong
Press Releases
Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®
May 23, 2025
·
7 min read
Mergers & acquisitions
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
The acquisition of Tubulis GmbH—Gilead Sciences’ latest of the year after buying Arcellx and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.
April 7, 2026
·
2 min read
·
Heather McKenzie
1 of 29,522
Next
